T1	CHEM 32 44	indometacina
#1	AnnotatorNotes T1	C0021246; indomethacin; Organic Chemical · Pharmacologic Substance
T2	ANAT 70 77	séricos
#2	AnnotatorNotes T2	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T3	CHEM 81 88	amilasa
#3	AnnotatorNotes T3	C0002712; amylase; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Enzyme
T4	PROC 103 149	colangiopancreatografía retrógrada endoscópica
#4	AnnotatorNotes T4	C0008310; Endoscopic Retrograde Cholangiopancreatography; Diagnostic Procedure
T5	DISO 195 207	pancreatitis
#5	AnnotatorNotes T5	C0030305; Pancreatitis; Disease or Syndrome
T6	DISO 234 249	hiperamilasemia
#6	AnnotatorNotes T6	C0221773; Hyperamylasemia; Disease or Syndrome
T7	DISO 252 270	pancreatitis aguda
#7	AnnotatorNotes T7	C0001339; Pancreatitis, Acute; Disease or Syndrome
T8	DISO 287 301	complicaciones
#8	AnnotatorNotes T8	C0009566; Complication; Pathologic Function
T9	PROC 339 385	colangiopancreatografía retrógrada endoscópica
#9	AnnotatorNotes T9	C0008310; Endoscopic Retrograde Cholangiopancreatography; Diagnostic Procedure
T10	PROC 387 391	CPRE
#10	AnnotatorNotes T10	C0008310; Endoscopic Retrograde Cholangiopancreatography; Diagnostic Procedure
T11	DISO 468 483	hiperamilasemia
#11	AnnotatorNotes T11	C0221773; Hyperamylasemia; Disease or Syndrome
T12	DISO 486 498	pancreatitis
#12	AnnotatorNotes T12	C0030305; Pancreatitis; Disease or Syndrome
T13	PROC 511 515	CPRE
#13	AnnotatorNotes T13	C0008310; Endoscopic Retrograde Cholangiopancreatography; Diagnostic Procedure
T14	PROC 518 537	evaluar la utilidad
T15	CHEM 541 553	indometacina
#14	AnnotatorNotes T15	C0021246; indomethacin; Organic Chemical · Pharmacologic Substance
T16	PROC 569 579	prevención
#15	AnnotatorNotes T16	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T17	PROC 821 834	procedimiento
#16	AnnotatorNotes T17	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T18	CHEM 775 787	indometacina
#17	AnnotatorNotes T18	C0021246; indomethacin; Organic Chemical · Pharmacologic Substance
T19	PROC 1400 1413	procedimiento
#18	AnnotatorNotes T19	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T20	CHEM 867 876	glicerina
#19	AnnotatorNotes T20	C0017861; glycerin; Organic Chemical · Biologically Active Substance · Pharmacologic Substance
T21	PROC 905 909	CPRE
#20	AnnotatorNotes T21	C0008310; Endoscopic Retrograde Cholangiopancreatography; Diagnostic Procedure
T22	CHEM 935 942	amilasa
#21	AnnotatorNotes T22	C0002712; amylase; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Enzyme
T23	ANAT 943 949	sérica
#22	AnnotatorNotes T23	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T24	PROC 1275 1286	diagnóstico
#23	AnnotatorNotes T24	C0011900; Diagnosis; Diagnostic Procedure
T25	DISO 1498 1513	hiperamilasemia
#24	AnnotatorNotes T25	C0221773; Hyperamylasemia; Disease or Syndrome
T26	DISO 1538 1553	hiperamilasemia
#25	AnnotatorNotes T26	C0221773; Hyperamylasemia; Disease or Syndrome
T27	DISO 1642 1654	pancreatitis
#26	AnnotatorNotes T27	C0030305; Pancreatitis; Disease or Syndrome
T28	DISO 1758 1774	eventos adversos
#27	AnnotatorNotes T28	C0877248; Adverse event; Pathologic Function | C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T29	CHEM 1791 1803	indometacina
#28	AnnotatorNotes T29	C0021246; indomethacin; Organic Chemical · Pharmacologic Substance
T30	PROC 1820 1824	CPRE
#29	AnnotatorNotes T30	C0008310; Endoscopic Retrograde Cholangiopancreatography; Diagnostic Procedure
T31	DISO 1848 1863	hiperamilasemia
#30	AnnotatorNotes T31	C0221773; Hyperamylasemia; Disease or Syndrome
T32	DISO 1866 1878	pancreatitis
#31	AnnotatorNotes T32	C0030305; Pancreatitis; Disease or Syndrome
T33	CHEM 1883 1895	indometacina
#32	AnnotatorNotes T33	C0021246; indomethacin; Organic Chemical · Pharmacologic Substance
T34	DISO 1944 1963	efectos secundarios
#33	AnnotatorNotes T34	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T35	PROC 14 28	administración
#34	AnnotatorNotes T35	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T36	PROC 62 88	niveles séricos de amilasa
#35	AnnotatorNotes T36	C0201885; Amylase measurement, serum (procedure); Laboratory Procedure
T37	PROC 611 636	ensayo clínico controlado
#36	AnnotatorNotes T37	C0206035; Controlled Clinical Trials, Randomized; Research Activity
T38	PROC 926 949	nivel de amilasa sérica
#37	AnnotatorNotes T38	C0201885; Amylase measurement, serum (procedure); Laboratory Procedure
T39	DISO 1035 1047	pancreatitis
#38	AnnotatorNotes T39	C0030305; Pancreatitis; Disease or Syndrome
T40	DISO 1290 1307	patología benigna
T42	Duration 660 668	12 meses
T43	LIVB 687 696	pacientes
#39	AnnotatorNotes T43	C0030705; Patients; Patient or Disabled Group
T44	Dose 795 801	100 mg
T45	Duration 802 809	2 horas
T46	Duration 878 887	Dos horas
T53	LIVB 1168 1175	mujeres
#40	AnnotatorNotes T53	C0043210; Woman; Population Group
T54	LIVB 1181 1188	hombres
#41	AnnotatorNotes T54	C0025266; Male population group; Population Group
T55	LIVB 1426 1435	pacientes
#42	AnnotatorNotes T55	C0030705; Patients; Patient or Disabled Group
T56	LIVB 1440 1458	grupo experimental
#43	AnnotatorNotes T56	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T59	LIVB 1570 1579	pacientes
#44	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T60	LIVB 1675 1684	pacientes
#45	AnnotatorNotes T60	C0030705; Patients; Patient or Disabled Group
T61	Neg_cue 1736 1738	No
T62	Neg_cue 1755 1757	ni
T63	Spec_cue 1838 1847	riesgo de
T64	Route 45 51	rectal
#46	AnnotatorNotes T64	C1527425; Rectal Route of Drug Administration; Functional Concept
T41	Route 554 560	rectal
#47	AnnotatorNotes T41	C1527425; Rectal Route of Drug Administration; Functional Concept
T65	Route 788 794	rectal
#48	AnnotatorNotes T65	C1527425; Rectal Route of Drug Administration; Functional Concept
T66	LIVB 838 845	control
#49	AnnotatorNotes T66	C0009932; Control Groups; Group
T67	LIVB 724 740	grupo de estudio
#50	AnnotatorNotes T67	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T47	Age 1203 1215	55,37 ± 18,0
T48	Age 1243 1254	51,1 ± 17,0
T49	LIVB 1263 1270	control
#51	AnnotatorNotes T49	C0009932; Control Groups; Group
T50	LIVB 1224 1240	grupo de estudio
#52	AnnotatorNotes T50	C2348561; Study Population (group); Population Group
T51	LIVB 1344 1360	grupo de estudio
#53	AnnotatorNotes T51	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T52	LIVB 1584 1600	grupo de estudio
#54	AnnotatorNotes T52	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T68	LIVB 1689 1705	grupo de estudio
#55	AnnotatorNotes T68	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T69	LIVB 1716 1723	control
#56	AnnotatorNotes T69	C0009932; Control Groups; Group
T70	LIVB 1610 1617	control
#57	AnnotatorNotes T70	C0009932; Control Groups; Group
T71	LIVB 1476 1483	control
#58	AnnotatorNotes T71	C0009932; Control Groups; Group
T72	Route 1804 1810	rectal
#59	AnnotatorNotes T72	C1527425; Rectal Route of Drug Administration; Functional Concept
T57	Neg_cue 1938 1943	nulos
T58	LIVB 1378 1385	control
#60	AnnotatorNotes T58	C0009932; Control Groups; Group
T73	DISO 1744 1754	mortalidad
#61	AnnotatorNotes T73	C1306577; Death (finding); Finding | C1546956; Patient Outcome - Died; Finding
A1	Assertion T28 Negated
A2	Assertion T31 Speculated
A3	Assertion T32 Speculated
A4	Assertion T34 Negated
A5	Assertion T73 Negated
R1	Negation Arg1:T61 Arg2:T73	
R2	Negation Arg1:T62 Arg2:T28	
T74	Observation 1 7	Efecto
#62	AnnotatorNotes T74	C1518681; Outcome of Therapy; Finding (?)
R3	Causes Arg1:T35 Arg2:T74	
R4	Used_for Arg1:T1 Arg2:T35	
R5	Has_Route_or_Mode Arg1:T1 Arg2:T64	
R7	Location_of Arg1:T2 Arg2:T36	
R8	After Arg1:T36 Arg2:T4	
T75	Quantifier_or_Qualifier 208 218	secundaria
R9	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T75	
R10	Before Arg1:T4 Arg2:T5	
R11	After Arg1:T7 Arg2:T9	
R12	After Arg1:T6 Arg2:T9	
R13	After Arg1:T7 Arg2:T10	
R14	After Arg1:T6 Arg2:T10	
R15	After Arg1:T8 Arg2:T9	
R16	After Arg1:T8 Arg2:T10	
R17	After Arg1:T12 Arg2:T13	
R18	After Arg1:T11 Arg2:T13	
R20	Has_Route_or_Mode Arg1:T15 Arg2:T41	
R21	Used_for Arg1:T15 Arg2:T16	
T76	CONC 669 682	se incluyeron
#63	AnnotatorNotes T76	C1512693; Inclusion; Qualitative Concept
R22	Has_Duration_or_Interval Arg1:T76 Arg2:T42	
R23	Experiences Arg1:T67 Arg2:T18	
R24	Has_Route_or_Mode Arg1:T18 Arg2:T65	
R25	Has_Dose_or_Strength Arg1:T18 Arg2:T44	
R26	Has_Duration_or_Interval Arg1:T18 Arg2:T45	
R27	Before Arg1:T18 Arg2:T17	
R28	Before Arg1:T35 Arg2:T4	
R29	Before Arg1:T15 Arg2:T13	
R31	Experiences Arg1:T66 Arg2:T20	
R32	Before Arg1:T20 Arg2:T17	
R33	Location_of Arg1:T23 Arg2:T38	
R34	After Arg1:T38 Arg2:T46	
R35	Before Arg1:T21 Arg2:T38	
T77	Quantifier_or_Qualifier 1048 1055	clínica
#64	AnnotatorNotes T77	C0205210; Clinical; Qualitative Concept
R36	Has_Quantifier_or_Qualifier Arg1:T39 Arg2:T77	
T78	CONC 1105 1124	criterios de Ranson
#65	AnnotatorNotes T78	C1623748; Ranson's criteria score (assessment scale); Quantitative Concept
R37	Has_Age Arg1:T50 Arg2:T47	
R38	Has_Age Arg1:T49 Arg2:T48	
R39	Experiences Arg1:T51 Arg2:T40	
R40	Experiences Arg1:T58 Arg2:T40	
R41	Before Arg1:T19 Arg2:T25	
R42	Experiences Arg1:T55 Arg2:T19	
R43	Experiences Arg1:T56 Arg2:T19	
R44	Experiences Arg1:T71 Arg2:T19	
R45	Experiences Arg1:T55 Arg2:T25	
R46	Experiences Arg1:T56 Arg2:T25	
R47	Experiences Arg1:T71 Arg2:T25	
R48	Experiences Arg1:T59 Arg2:T26	
R49	Experiences Arg1:T52 Arg2:T26	
R50	Experiences Arg1:T70 Arg2:T26	
R51	Experiences Arg1:T60 Arg2:T27	
R52	Experiences Arg1:T68 Arg2:T27	
T79	Quantifier_or_Qualifier 1655 1659	leve
R53	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T79	
R54	Experiences Arg1:T69 Arg2:T27	
R55	Has_Route_or_Mode Arg1:T29 Arg2:T72	
R56	Before Arg1:T29 Arg2:T30	
R57	Speculation Arg1:T63 Arg2:T31	
R58	Speculation Arg1:T63 Arg2:T32	
R60	Before Arg1:T30 Arg2:T31	
R61	Before Arg1:T30 Arg2:T32	
R62	Negation Arg1:T57 Arg2:T34	
R63	Before Arg1:T33 Arg2:T34	
#67	AnnotatorNotes T75	C0175668; Secondary to; Qualitative Concept
#66	AnnotatorNotes T79	C2945599; Mild (qualifier value); Qualitative Concept
A6	Experiencer T53 Patient
A7	Experiencer T54 Patient
A8	Experiencer T49 Patient
A9	Experiencer T50 Patient
A10	Experiencer T58 Patient
A11	Experiencer T51 Patient
A12	Experiencer T71 Patient
A13	Experiencer T56 Patient
A14	Experiencer T55 Patient
A15	Experiencer T59 Patient
A16	Experiencer T52 Patient
A17	Experiencer T70 Patient
A18	Experiencer T69 Patient
A19	Experiencer T68 Patient
A20	Experiencer T60 Patient
A21	Experiencer T43 Patient
A22	Experiencer T67 Patient
A23	Experiencer T66 Patient
